lixisenatide vs Semaglutide (Ozempic)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi and partners
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)
Result source: NCT00707031
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)
Result source: NCT03819153
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | lixisenatide | Semaglutide (Ozempic) |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT0179870619 other results
| -1.6% vs 0%−1.6 vs placeboNCT0205489735 other results
|
| Body weight, change (kg) | -0.6 vs 1.0vs Insulin GlulisineNCT0176855917 other results
| -4.9 vs -0.6−4.3 vs placeboNCT0172044632 other results
|
| HbA1c below 7% | 53% vs 38.8%+14.2 vs placeboNCT0116977910 other results
| 72.3% vs 24.8%+47.5 vs placeboNCT0205489710 other results
|
| Fasting plasma glucose, change | -0.3 vs 0.0−0.3 vs placeboNCT0179870617 other results
| -2.1 vs -0.9−1.2 vs placeboNCT0172044624 other results
|
| 3-point MACE (% with event) | —Not reported | 6.6% vs 8.9%−2.3 vs placeboNCT017204461 other result
|
HbA1c, change
- lixisenatide
- -0.6% vs 0.1%−0.6 vs placeboNCT01798706
19 other results
- -0.8% vs -0.5% NCT01169779
- -0.7% vs -0.4% NCT00975286
- -0.9% vs -0.3% NCT00763815
- -0.7% vs -0.4% NCT00715624
- -0.8% vs -0.1% NCT00713830
- -0.8% vs -0.4% NCT00763451
- -0.9% vs -0.4% NCT00763451
- -0.8% vs 0.1% NCT00866658
- -1.1% vs -0.6% NCT02058160
- -1.6% vs -1.3% NCT02058147
- -0.8% vs -1.3% NCT02058147
- -0.6% vs -0.8% NCT01768559
- -0.8% vs -1.0% NCT00707031
- -1.9% vs -1.7% NCT05413369
- -1.9% vs -1.7% NCT05413369
- -0.7% vs -0.7% NCT00976937
- -1.8% vs -1.6% NCT01476475
- -0.6% vs -0.7% NCT01596504
- -0.3% vs -0.5% NCT01175473
- Semaglutide (Ozempic)
- -1.6% vs 0%−1.6 vs placeboNCT02054897
35 other results
- -1.9% vs -0.1% NCT02305381
- -1.6% vs -0.2% NCT03086330
- -1.5% vs 0% NCT02054897
- -1.4% vs -0.1% NCT02305381
- -1.6% vs -0.8% NCT02128932
- -1.7% vs -1.1% NCT03191396
- -1.8% vs -1.1% NCT02648204
- -1.5% vs -0.9% NCT01885208
- -1.6% vs -0.6% NCT01930188
- -1.2% vs -0.8% NCT02128932
- -1.5% vs -1.1% NCT02648204
- -1.3% vs -0.6% NCT01930188
- -1.4% vs -0.7% NCT05514535
- -1.5% vs -1.2% NCT03689374
- -1.4% vs -0.4% NCT01720446
- -1.1% vs -0.4% NCT01720446
- -0.9% vs -0.0% NCT03819153
- -1.8% vs -0.3% NCT05649137
- -0.8% vs 0.2% NCT04560998
- -2.2% vs -0.7% NCT02254291
- -2.0% vs -0.7% NCT02207374
- -1.9% vs -0.7% NCT02254291
- -1.7% vs -0.7% NCT02207374
- -1.4% vs -0.7% NCT05514535
- -1.9% vs -1.1% NCT05486065
- -1.1% vs -0.4% NCT05144984
- -2.1% vs -1.1% NCT05486065
- -1.8% vs -1.1% NCT05486065
- -2.3% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.3% vs -0.4% NCT05144984
- -0.5% vs 0% NCT04538352
- -1.5% vs -1.1% NCT03596450
- -1.4% vs -1.0% NCT03596450
Body weight, change (kg)
- lixisenatide
- -0.6 vs 1.0vs Insulin GlulisineNCT01768559
17 other results
- -1.5 vs -0.2 NCT01798706
- -1.5 vs -1.2 NCT01169779
- 0.3 vs 1.2 NCT00975286
- -0.2 vs 0.2 NCT00763815
- -1.8 vs -0.5 NCT00715624
- -1.8 vs -0.9 NCT00713830
- -2.7 vs -1.6 NCT00763451
- -2.6 vs -1.6 NCT00763451
- -0.4 vs 0.1 NCT00866658
- -0.7 vs 0.7 NCT02058160
- -0.3 vs 1.1 NCT02058147
- -2.3 vs 1.1 NCT02058147
- -3.0 vs -4.0 NCT00707031
- -0.3 vs 1.2 NCT05413369
- -2.5 vs -1.2 NCT00976937
- -1.0 vs 0.5 NCT01476475
- -1.6 vs -2.4 NCT01596504
- Semaglutide (Ozempic)
- -4.9 vs -0.6−4.3 vs placeboNCT01720446
32 other results
- -3.6 vs -0.6 NCT01720446
- -5.5 vs -1.4 NCT03819153
- -4.7 vs -0.9 NCT02054897
- -6.4 vs -1.4 NCT02305381
- -4.7 vs -1 NCT03086330
- -3.7 vs -0.9 NCT02054897
- -3.7 vs -1.4 NCT02305381
- -14.9 vs -4.6 NCT05649137
- -5.2 vs -1.2 NCT04560998
- -5.2 vs 1.1 NCT02128932
- -4.2 vs -0.4 NCT03061214
- -5.8 vs -2 NCT03191396
- -6.5 vs -2.3 NCT02648204
- -5.6 vs -1.9 NCT01885208
- -6.1 vs -1.9 NCT01930188
- -3.5 vs 1.1 NCT02128932
- -3 vs -0.4 NCT03061214
- -4.6 vs -2.3 NCT02648204
- -4.3 vs -1.9 NCT01930188
- -8.0 vs 0.4 NCT05514535
- -4.2 vs 2.9 NCT03689374
- -5.7 vs -4.3 NCT03136484
- -8.9 vs -2.3 NCT05486065
- -4.7 vs -2.6 NCT05144984
- -13.1 vs -2.3 NCT05486065
- -10.1 vs -2.3 NCT05486065
- -8.9 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -10 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -5 vs -3.1 NCT03596450
- -8.6 vs 1.4 NCT04538352
HbA1c below 7%
- lixisenatide
- 53% vs 38.8%+14.2 vs placeboNCT01169779
10 other results
- 56.3% vs 38.5% NCT00975286
- 52.3% vs 26.4% NCT00763815
- 28.3% vs 12% NCT00715624
- 36.4% vs 13.5% NCT00713830
- 42.1% vs 24.1% NCT00763451
- 47.4% vs 24.1% NCT00763451
- 35.6% vs 5.2% NCT00866658
- 48.5% vs 49.8% NCT00707031
- 72.5% vs 59.8% NCT05413369
- 40.7% vs 40% NCT00976937
- Semaglutide (Ozempic)
- 72.3% vs 24.8%+47.5 vs placeboNCT02054897
10 other results
- 78.6% vs 10.5% NCT02305381
- 82.5% vs 20.5% NCT03086330
- 74.2% vs 24.8% NCT02054897
- 60.6% vs 10.5% NCT02305381
- 78.7% vs 52.2% NCT02648204
- 84% vs 49.6% NCT03061214
- 80.4% vs 45.9% NCT03191396
- 68.4% vs 52.2% NCT02648204
- 74.5% vs 49.6% NCT03061214
- 76.1% vs 50.8% NCT03136484
Fasting plasma glucose, change
- lixisenatide
- -0.3 vs 0.0−0.3 vs placeboNCT01798706
17 other results
- -0.7 vs -0.2 NCT01169779
- 0.3 vs 0.5 NCT00975286
- -1.2 vs -0.3 NCT00763815
- -0.6 vs -0.6 NCT00715624
- -1.0 vs -0.4 NCT00713830
- -0.6 vs 0.1 NCT00763451
- -0.5 vs 0.1 NCT00763451
- -0.4 vs 0.3 NCT00866658
- -0.3 vs -0.5 NCT02058160
- -3.5 vs -3.3 NCT02058147
- -1.5 vs -3.3 NCT02058147
- -0.2 vs -0.2 NCT01768559
- -1.2 vs -1.4 NCT00707031
- -3.2 vs -3.5 NCT05413369
- -0.5 vs -0.7 NCT00976937
- -3.4 vs -3.5 NCT01476475
- 0.1 vs 0.1 NCT01596504
- Semaglutide (Ozempic)
- -2.1 vs -0.9−1.2 vs placeboNCT01720446
24 other results
- -1.8 vs -0.9 NCT01720446
- -2.4 vs -0.6 NCT02054897
- -2.4 vs -0.5 NCT02305381
- -2.3 vs 0.1 NCT03086330
- -2.4 vs -0.6 NCT02054897
- -1.6 vs -0.5 NCT02305381
- -3.3 vs -1.1 NCT05649137
- -2.7 vs -2.1 NCT02128932
- -2.6 vs -1 NCT03061214
- -2.6 vs -1.5 NCT03191396
- -2.8 vs -1.9 NCT02648204
- -2.8 vs -2 NCT01885208
- -2.6 vs -1.1 NCT01930188
- -2.0 vs -2.1 NCT02128932
- -2.2 vs -1.9 NCT02648204
- -2.1 vs -1.1 NCT01930188
- -1.3 vs -0.8 NCT03689374
- -2.2 vs -1 NCT03061214
- -2.5 vs -2 NCT03136484
- -1.4 vs -0.1 NCT05144984
- -3.9 vs -0.1 NCT05144984
- -3.4 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
3-point MACE (% with event)
- lixisenatide
- —Not reported
- Semaglutide (Ozempic)
- 6.6% vs 8.9%−2.3 vs placeboNCT01720446
1 other result
- 12% vs 14.4% NCT03819153
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
15 other shared endpoints and safety
Coverage. lixisenatide: 19 of 19 rows · Semaglutide (Ozempic): 19 of 19 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | lixisenatide Rows use multiple source trials | Semaglutide (Ozempic) Rows use multiple source trials |
|---|---|---|
| DTSQ-c absolute change · score | 0.88 vs 0.65 placebo score @ 24wka,b,c NCT00975286 · Phase 3 · registry result, not featured evidence | 4.55 vs 4.52 Dulaglutide score @ 40wk1.0 mgd,a,b,c NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose4.6 vs 4.52 Dulaglutide score @ 40wk0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.57 mmol/L @ 24wkd,e,a,b NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.35 mmol/L @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -1.45 mmol/L @ 24wk*e,a,b NCT05533632 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -26.2 mg/dL as posted |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.74% (n=222) @ 24wkd,e,a,b NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.65% (n=218) @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -1.6% (n=92) @ 24wke,a,b NCT05533632 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain responder rate · % of participants | 19.9% (n=366) vs 9% (n=365) Insulin Glargine @ 30wkf,a,b NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials31.8% (n=468) vs 18.9% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence 26.2% (n=233) vs 18.9% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence | 76.9% (n=238) vs 33.7% (n=249) Sitagliptin @ 30wk1.0 mg weeklyd,f,a,b NCT03061214 · Phase 3 · registry result, not featured evidence show 1 more dose66% (n=235) vs 33.7% (n=249) Sitagliptin @ 30wk0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 40.6% (n=239) @ 24wkd,a,b,c NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose43% (n=244) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence | 67.6% (n=480) @ 40wk2.0 mg weeklyd,a,b,c NCT03989232 · Phase 3 show 1 more dose57.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 28.5% (n=295) vs 35.4% (n=297) Exenatide @ 24wkf,a,g NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 9 other source trials32.4% (n=185) vs 18.1% (n=188) placebo @ 24wk NCT01169779 · Phase 3 · registry result, not featured evidence 32.1% (n=215) vs 16.3% (n=221) placebo @ 24wk NCT00975286 · Phase 3 · registry result, not featured evidence 28.9% (n=308) vs 10.1% (n=148) placebo @ 24wk NCT00763815 · Phase 3 · registry result, not featured evidence 24% (n=150) vs 26.3% (n=160) Sitagliptin @ 24wk NCT00976937 · Phase 3 · registry result, not featured evidence 14.5% (n=304) vs 3.8% (n=158) placebo @ 24wk NCT00715624 · Phase 3 · registry result, not featured evidence 19.3% (n=544) vs 4.7% (n=274) placebo @ 24wk NCT00713830 · Phase 3 · registry result, not featured evidence 25.6% (n=156) vs 7.6% (n=158) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 20.4% (n=152) vs 7.6% (n=158) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 17.8% (n=146) vs 1.3% (n=154) placebo @ 24wk NCT00866658 · Phase 3 · registry result, not featured evidence | 62.1% (n=293) vs 26.8% (n=313) Canagliflozin @ 52wkf,a,g Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants No placebo or comparator arm | 19.2% (n=239) @ 24wkd,a,b,c NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose23.8% (n=244) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence | 51.7% (n=480) @ 40wk2.0 mg weeklyd,a,b,c NCT03989232 · Phase 3 show 1 more dose38.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| Hypoglycemia Event Incidence responder rate · % of participants | 40% (n=365) vs 42.5% (n=365) Insulin Glarginea,b,h NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials25.6% (n=469) vs 23.6% (n=467) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence 6.4% (n=233) vs 23.6% (n=467) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence | 1.7% (n=300) vs 1% (n=299) Dulaglutide1.0 mgd,a,b,h NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose0.7% (n=301) vs 1% (n=299) Dulaglutide0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence |
| PPG Excursion absolute change · mmol/L | -3.9 vs -0.47 Insulin Glargine mmol/L @ 30wka,b NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials-2.31 vs -0.18 Insulin Glargine mmol/L @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence -3.23 vs -0.18 Insulin Glargine mmol/L @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence | -1.2 vs -0.7 Sitagliptin mmol/L @ 30wk1.0 mg weeklyd,a,b NCT03061214 · Phase 3 · registry result, not featured evidence show 1 more dose-1 vs -0.7 Sitagliptin mmol/L @ 30wk0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L | -1.5 vs -0.6 Insulin Glargine mmol/L @ 30wka,b NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials-3.35 vs -2.66 Insulin Glargine mmol/L @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence -1.95 vs -2.66 Insulin Glargine mmol/L @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence | -3.3 vs -1.6 Sitagliptin mmol/L @ 30wk1.0 mg weeklyd,a,b NCT03061214 · Phase 3 · registry result, not featured evidence show 1 more dose-2.5 vs -1.6 Sitagliptin mmol/L @ 30wk0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L No placebo or comparator arm | -1.1 mmol/L @ 24wkd,a,b,g NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.8 mmol/L @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -1.69 mmol/L @ 52wka,b,g NCT05813912 · Phase 3 · registry result, not featured evidence · combination |
| Waist Circumference Change absolute change · cm | -1.4 vs -1.93 Liraglutide cm @ 8wk20 µgi,j,b,k NCT01596504 · Phase 2 · registry result, not featured evidence | -12.6 vs -6.5 placebo cm @ 72wk7.2 mgi,j,b,k NCT05649137 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -2.8 kg @ 24wkd,e,a,b NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-2.6 kg @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -5.3 kg @ 24wke,a,b NCT05533632 · Phase 4 · registry result, not featured evidence |
| Weight Loss 5% responder rate · % of participants | 25.1% (n=295) vs 31.4% (n=296) Exenatide @ 24wkf,a,g NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 8 other source trials19.7% (n=188) vs 14.7% (n=191) placebo @ 24wk NCT01169779 · Phase 3 · registry result, not featured evidence 5.1% (n=217) vs 3.2% (n=220) placebo @ 24wk NCT00975286 · Phase 3 · registry result, not featured evidence 9.2% (n=315) vs 5.1% (n=157) placebo @ 24wk NCT00763815 · Phase 3 · registry result, not featured evidence 13.2% (n=311) vs 3.1% (n=161) placebo @ 24wk NCT00715624 · Phase 3 · registry result, not featured evidence 14.4% (n=554) vs 7.2% (n=278) placebo @ 24wk NCT00713830 · Phase 3 · registry result, not featured evidence 19.6% (n=158) vs 15.2% (n=158) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 25.8% (n=155) vs 15.2% (n=158) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 7.3% (n=150) vs 4.5% (n=157) placebo @ 24wk NCT00866658 · Phase 3 · registry result, not featured evidence | 52.7% (n=298) vs 47% (n=313) Canagliflozin @ 52wkf,a,g Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| Weight Loss 5% responder rate · % of participants No placebo or comparator arm | 19.3% (n=249) @ 24wkd,a,b,c NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose14.9% (n=248) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence | 59.2% (n=480) @ 40wk2.0 mg weeklyd,a,b,c NCT03989232 · Phase 3 show 1 more dose51.3% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| Dropout rate | 32.5%l NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.2%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 8.3%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 3.5% NCT01147250 · Phase 3 11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 5.8% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 10.5%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 12.4%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 11.9% NCT01798706 · Phase 3 · registry result, not featured evidence 10.1% NCT01768559 · Phase 3 · registry result, not featured evidence 10.6%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 16%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 8.7% NCT01169779 · Phase 3 · registry result, not featured evidence 13% NCT00975286 · Phase 3 · registry result, not featured evidence 26% NCT00763815 · Phase 3 · registry result, not featured evidence 27.5%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 22.4%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 10.1% NCT00976937 · Phase 3 · registry result, not featured evidence 35.3% NCT00715624 · Phase 3 · registry result, not featured evidence 30.9% NCT00713830 · Phase 3 · registry result, not featured evidence 18.6%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 24.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 25%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 39.4%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 13.6% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 4.2%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 6.8% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence | 1.3%1.0 mgm NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results1.7%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.4% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 7.8%0.5 mg weekly NCT02054897 · Phase 3 5.1%1.0 mg weekly NCT01930188 · Phase 3 · combination 5.4%0.5 mg weekly NCT01930188 · Phase 3 · combination 5.3%1.0 mg/week NCT02128932 · Phase 3 7.5%0.5 mg/week NCT02128932 · Phase 3 3.8%2.0 mg weekly NCT03989232 · Phase 3 2.1%1.0 mg weekly NCT03989232 · Phase 3 3.8%1.0 mg weekly NCT02305381 · Phase 3 3.8%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 10.6% NCT05533632 · Phase 4 · registry result, not featured evidence 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 28.1% NCT03596450 · Phase 4 · registry result, not featured evidence 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination 1.7%Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 3.9%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 18.3%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 7.6% NCT04560998 · Phase 3 · registry result, not featured evidence 1.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence 9.7%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 8.7%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.9% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 2.6%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7.3%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 4.1%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.5%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.9%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 8.2%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 11.3%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 12.9%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 3.9%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.7%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 14.1%l NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results2.5%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 4.2%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 — NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.3% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 3.9%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence — NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 8.5% NCT01798706 · Phase 3 · registry result, not featured evidence 5% NCT01768559 · Phase 3 · registry result, not featured evidence 4.9%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 4.4%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 5.6% NCT01169779 · Phase 3 · registry result, not featured evidence 8.5% NCT00975286 · Phase 3 · registry result, not featured evidence 9% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 2.5% NCT00976937 · Phase 3 · registry result, not featured evidence 11.2% NCT00715624 · Phase 3 · registry result, not featured evidence 12.4% NCT00713830 · Phase 3 · registry result, not featured evidence 8.7%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 11.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 13.9%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 21.2%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 9.1% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 2.1%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 3.7% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence | —1.0 mgm NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results—0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT03819153 · Phase 3 —1.0 mg weekly NCT02054897 · Phase 3 —0.5 mg weekly NCT02054897 · Phase 3 —1.0 mg weekly NCT01930188 · Phase 3 · combination —0.5 mg weekly NCT01930188 · Phase 3 · combination —1.0 mg/week NCT02128932 · Phase 3 —0.5 mg/week NCT02128932 · Phase 3 —2.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT02305381 · Phase 3 —0.5 mg weekly NCT02305381 · Phase 3 — NCT04126603 · Phase 4 · registry result, not featured evidence — NCT05786521 · Phase 4 · registry result, not featured evidence 3.8% NCT05533632 · Phase 4 · registry result, not featured evidence —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 2.2% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination —7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence —1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence — NCT04560998 · Phase 3 · registry result, not featured evidence — NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence —0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence — NCT03136484 · Phase 3 · registry result, not featured evidence · combination —1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 0%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence —2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence —2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 8.2%l NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results0%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 0.8%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 20.6% NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 5.2% NCT05413369 · Phase 3 · registry result, not featured evidence 3.9%Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence 10.2%Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination 5.5% NCT02058160 · Phase 3 · registry result, not featured evidence 3.8%Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 3.9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 4.5% NCT01798706 · Phase 3 · registry result, not featured evidence 3.7% NCT01768559 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 1.5% NCT01169779 · Phase 3 · registry result, not featured evidence 7.6% NCT00975286 · Phase 3 · registry result, not featured evidence 7.7% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 1.9% NCT00976937 · Phase 3 · registry result, not featured evidence 14% NCT00715624 · Phase 3 · registry result, not featured evidence 10.1% NCT00713830 · Phase 3 · registry result, not featured evidence —Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 13%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 9.9%Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 2.8%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.1%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.5% NCT00866658 · Phase 3 · registry result, not featured evidence 2.1%20 µg NCT01596504 · Phase 2 · registry result, not featured evidence —20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 5.6% NCT01476475 · Phase 2 · registry result, not featured evidence 0% NCT01175473 · Phase 2 · registry result, not featured evidence | 33.6%1.0 mgm NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results35%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 9.4%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 49.6% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 5.5%0.5 mg weekly NCT02054897 · Phase 3 7.3%1.0 mg weekly NCT01930188 · Phase 3 · combination 7.3%0.5 mg weekly NCT01930188 · Phase 3 · combination 4.7%1.0 mg/week NCT02128932 · Phase 3 6.1%0.5 mg/week NCT02128932 · Phase 3 4.4%2.0 mg weekly NCT03989232 · Phase 3 5.2%1.0 mg weekly NCT03989232 · Phase 3 9.2%1.0 mg weekly NCT02305381 · Phase 3 6.1%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 1% NCT05533632 · Phase 4 · registry result, not featured evidence 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 6% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 5.9%INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 9.8%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 19.7%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 18.7% NCT04560998 · Phase 3 · registry result, not featured evidence 6.2% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 7.4% NCT03689374 · Phase 3 · registry result, not featured evidence 6.6%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.3%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 4.6% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 5.9%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 4.7%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7.7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5.6%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 7.9%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 5.8%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 6.7%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 1.6%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.3%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 2.6%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 7.8%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 6.5%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 4.1%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | l nausea 28.6% nasopharyngitis 15.4% diarrhoea 15.1% NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 31 more resultsnausea 20.2% (placebo 3.3%) headache 7.6% (placebo 8.2%) vomiting 6.7% (placebo 0%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 24.2% (placebo 3.3%) headache 8.3% (placebo 8.2%) dizziness 7.5% (placebo 3.3%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 21.7% (placebo 5.9%) hypoglycaemia 20.1% (placebo 18.3%) dizziness 8.5% (placebo 6.3%) NCT01147250 · Phase 3 hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 17.2% covid-19 13.4% nausea 12.1% NCT05413369 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.8% nausea 8.6% diarrhoea 5.5% NCT02787551 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% nausea 9.2% diarrhoea 7.3% NCT02787551 · Phase 3 · registry result, not featured evidence mild asymptomatic hypoglycaemia 33.3% hypercholesterolaemia 22.2% mild gastrointestinal complaints 22.2% NCT02168491 · Phase 3 · registry result, not featured evidence · combination nausea 10.4% nasopharyngitis 8.8% headache 5.8% NCT02058160 · Phase 3 · registry result, not featured evidence nausea 9.6% diarrhoea 9% upper respiratory tract infection 7% NCT02058147 · Phase 3 · registry result, not featured evidence nausea 25% (placebo 7.5%) hypoglycaemia 17% (placebo 10.3%) diarrhoea 10.8% (placebo 7.5%) NCT01798706 · Phase 3 · registry result, not featured evidence hypoglycaemia 35.9% nausea 25.2% blood glucose decreased 20.1% NCT01768559 · Phase 3 · registry result, not featured evidence nausea 15.5% headache 7.1% nasopharyngitis 7.1% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 14.7% nasopharyngitis 9.8% hypoglycaemia 6.7% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 16.3% (placebo 2.6%) hypoglycaemia 9.2% (placebo 4.6%) dizziness 8.7% (placebo 4.1%) NCT01169779 · Phase 3 · registry result, not featured evidence hypoglycaemia 27.4% (placebo 19.3%) nausea 27.4% (placebo 4.9%) headache 9.9% (placebo 3.6%) NCT00975286 · Phase 3 · registry result, not featured evidence nausea 26% (placebo 13.7%) nasopharyngitis 16.4% (placebo 14.9%) headache 13.3% (placebo 11.8%) NCT00763815 · Phase 3 · registry result, not featured evidence nausea 24.7% (placebo 10.6%) headache 16.5% (placebo 23.5%) vomiting 15.7% (placebo 3.5%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 25.1% (placebo 10.6%) headache 19.2% (placebo 23.5%) diarrhoea 15.3% (placebo 11.8%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 17.7% headache 12.7% diarrhoea 8.9% NCT00976937 · Phase 3 · registry result, not featured evidence hypoglycaemia 42.1% (placebo 40.7%) nausea 29.3% (placebo 9.6%) headache 12.5% (placebo 10.2%) NCT00715624 · Phase 3 · registry result, not featured evidence nausea 28% (placebo 8.8%) hypoglycaemia 24.4% (placebo 19.3%) nasopharyngitis 15.9% (placebo 20.4%) NCT00713830 · Phase 3 · registry result, not featured evidence nausea 37.9% (placebo 8.1%) vomiting 18% (placebo 0.6%) diarrhoea 14.9% (placebo 13.1%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 29.2% (placebo 8.1%) vomiting 13% (placebo 0.6%) headache 12.4% (placebo 12.5%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 50% nasopharyngitis 36.1% decreased appetite 19.4% NCT00905255 · Phase 3 · registry result, not featured evidence nausea 36.4% nasopharyngitis 27.3% decreased appetite 18.2% NCT00905255 · Phase 3 · registry result, not featured evidence hypoglycaemia 43.5% (placebo 23.6%) nausea 39.6% (placebo 4.5%) vomiting 18.2% (placebo 1.9%) NCT00866658 · Phase 3 · registry result, not featured evidence 20 µg decreased appetite 18.8% nausea 18.8% nasopharyngitis 12.5% NCT01596504 · Phase 2 · registry result, not featured evidence nausea 7.5% nasopharyngitis 5.6% headache 5% NCT01476475 · Phase 2 · registry result, not featured evidence nausea 22.1% decreased appetite 18.2% headache 11.7% NCT01175473 · Phase 2 · registry result, not featured evidence | 1.0 mgm nausea 21.8% (placebo 7.5%) diarrhoea 18% (placebo 11.8%) vomiting 14.8% (placebo 5.1%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 42 more results0.5 mg diarrhoea 17.9% (placebo 11.8%) nausea 17.3% (placebo 7.5%) lipase increased 11.4% (placebo 8%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 1.0 mg nausea 22.3% diarrhoea 11.4% lipase increased 10.1% NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.0 mg weekly nausea 23.8% (placebo 7.8%) diarrhoea 10.8% (placebo 2.3%) headache 6.9% (placebo 6.2%) NCT02054897 · Phase 3 0.5 mg weekly nausea 20.3% (placebo 7.8%) diarrhoea 12.5% (placebo 2.3%) headache 11.7% (placebo 6.2%) NCT02054897 · Phase 3 1.0 mg weekly nausea 16.8% (placebo 4.5%) vomiting 11.5% (placebo 3%) diarrhoea 6.9% (placebo 1.5%) NCT02305381 · Phase 3 0.5 mg weekly nausea 11.4% (placebo 4.5%) lipase increased 9.1% (placebo 3%) nasopharyngitis 8.3% (placebo 10.5%) NCT02305381 · Phase 3 abdominal pain 60% NCT05786521 · Phase 4 · registry result, not featured evidence once weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nausea 18.4% diarrhoea 13.5% vomiting 9.7% NCT05514535 · Phase 3 · registry result, not featured evidence · combination 7.2 mg nausea 29% (placebo 11.8%) diarrhoea 18.2% (placebo 8.8%) vomiting 16.6% (placebo 2.9%) NCT05649137 · Phase 3 · registry result, not featured evidence 1.0 mg covid-19 5.6% (placebo 0%) decreased appetite 5.6% (placebo 0%) diabetic retinopathy 5.6% (placebo 5.7%) NCT04865770 · Phase 3 · registry result, not featured evidence covid-19 7.6% (placebo 5.3%) nausea 5.6% (placebo 0.8%) NCT04560998 · Phase 3 · registry result, not featured evidence covid-19 14.4% diarrhoea 12.1% nausea 11.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 14.8% diarrhoea 7.4% nasopharyngitis 6.5% NCT03689374 · Phase 3 · registry result, not featured evidence 1.0 mg weekly diarrhoea 16.9% nausea 13.4% upper respiratory tract infection 13.1% NCT03061214 · Phase 3 · registry result, not featured evidence 0.5 mg weekly diarrhoea 20.2% upper respiratory tract infection 9.8% lipase increased 7.7% NCT03061214 · Phase 3 · registry result, not featured evidence nausea 22.7% diarrhoea 15.1% vomiting 12.8% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1.0 mg nausea 21.5% diarrhoea 15.6% decreased appetite 10.4% NCT03191396 · Phase 3 · registry result, not featured evidence 1.0 mg weekly nausea 19.3% (placebo 3.3%) diarrhoea 11.3% (placebo 6%) vomiting 9.3% (placebo 2%) NCT03086330 · Phase 3 · registry result, not featured evidence 1.0 mg nausea 21% diarrhoea 13.7% vomiting 10.3% NCT02648204 · Phase 3 · registry result, not featured evidence 0.5 mg nausea 22.3% diarrhoea 14.3% vomiting 10% NCT02648204 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 31.1% nausea 19.1% diarrhoea 15.8% NCT02207374 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 33.9% constipation 18.4% nausea 12.1% NCT02207374 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 17.6% nausea 12.7% constipation 11.8% NCT02254291 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16.5% constipation 14.6% nausea 10.7% NCT02254291 · Phase 3 · registry result, not featured evidence 2.0 mg nausea 21.7% (placebo 15.3%) vomiting 18.3% (placebo 6.8%) diarrhoea 15% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 16.0 mg nausea 37.1% (placebo 15.3%) vomiting 25.8% (placebo 6.8%) diarrhoea 21% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 8.0 mg nausea 41.7% (placebo 15.3%) diarrhoea 33.3% (placebo 11.9%) vomiting 23.3% (placebo 6.8%) NCT05486065 · Phase 2 · registry result, not featured evidence 21.6 mg injection site erythema 10.2% (placebo 0%) injection site reaction 10.2% (placebo 0%) diarrhoea 8.5% (placebo 11.5%) NCT05144984 · Phase 2 · registry result, not featured evidence 2.4 mg + 12.0 mg diarrhoea 14.3% (placebo 11.5%) constipation 9.1% (placebo 1.6%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 2.4 mg nausea 19.5% (placebo 1.6%) diarrhoea 14.3% (placebo 11.5%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 21.6 mg diarrhoea 13% (placebo 11.5%) nausea 13% (placebo 1.6%) covid-19 11.7% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 7.2 mg diarrhoea 21.6% (placebo 11.5%) lipase increased 12.2% (placebo 3.3%) nausea 12.2% (placebo 1.6%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 40 weeks versus 24 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 4 versus Phase 3.
- fThe reported result categories differ.
- gAssessment timepoints differ: 52 weeks versus 24 weeks.
- hThe assessment timepoint is not available for both results.
- iTrial phases differ: Phase 3 versus Phase 2.
- jPopulation context differs: registered conditions differ.
- kAssessment timepoints differ: 72 weeks versus 8 weeks.
- lPopulation comparability has not been reviewed for 32 of these studies.
- mPopulation comparability has not been reviewed for 43 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
lixisenatide
show 15 more results
show 1 more result
show 3 more results
+ 54 further endpoints in the CSV export.
Semaglutide (Ozempic)
show 1 more result
show 13 more results
show 7 more results
show 1 more result
+ 100 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · Semaglutide (Ozempic)'s landscape